| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 4, 2011Presentations Cover Stents and Balloons for Coronary and Peripheral Artery Disease, Transcatheter Valve for Aortic Stenosis, Stent Grafts for Aortic Aneurysms, and Renal Denervation for Treatment-Resistant Hypertension and Heart Failure
MINNEAPOLIS, Nov 04, 2011 (BUSINESS WIRE) -- Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT)...
-
Oct 27, 2011
MINNEAPOLIS, Oct 27, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices advisory panel voted against...
-
Oct 10, 2011First Ever Randomized, Controlled Clinical Trial in Persistent Atrial Fibrillation (AF) Patients
VENICE, Italy & MINNEAPOLIS, Oct 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc.(NYSE: MDT) today announced results from its Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) clinical...
-
May 5, 2011
MINNEAPOLIS & SAN FRANCISCO, May 05, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced findings from the DISCERN AF trial, which utilized Medtronic's Reveal(R) XT insertable...
-
May 5, 2011Results Provide Evidence Supporting Potential Expansion of Indications for CRT in Symptomatic, Permanent Atrial Fibrillation Patient Population
MINNEAPOLIS & SAN FRANCISCO, May 05, 2011 (BUSINESS WIRE) -- Data presented as a Late Breaking Clinical Trial at Heart Rhythm 2011, the Heart Rhythm Society's 32nd Annual Scientific Sessions,...
-
May 2, 2011New Technology Adds Diagnostic Capability to the Arctic Front(R) Cardiac CryoAblation Catheter System in Treating Paroxysmal Atrial Fibrillation
MINNEAPOLIS, May 02, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval for use, and the first patient procedure using the...
-
Mar 28, 2011Late-Breaking Clinical Trials Feature One-Year Results of RESOLUTE US Study; Latest Evidence from Comprehensive Research Program Completes FDA Approval Submission
MINNEAPOLIS, Mar 28, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), today announced the imminent release of the pivotal U.S. data on its Resolute(R) drug-eluting stent (DES) at ACC.11, the 60th
-
Mar 4, 2011Innovative Technology Designed to Optimize Arctic Front(R) Cardiac CryoAblation Catheter System in the Treatment of Paroxysmal Atrial Fibrillation
MINNEAPOLIS & TOLOCHENAZ, Switzerland, Mar 04, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced the European launch of the Achieve(TM) Mapping Catheter, an intra-cardiac...
-
Jan 13, 2011Interventional Therapy Addresses Uncontrolled Hypertension with Renal Denervation
MINNEAPOLIS & MOUNTAIN VIEW, Calif., Jan 13, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), today announced that it has completed the acquisition of privately-held Ardian, Inc., a developer...
-
Dec 17, 2010New Arctic Front(R) Cardiac CryoAblation Catheter System Reduces Symptoms for Patients with Common Heart Rhythm Disorder
MINNEAPOLIS, Dec 17, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced that the U.S. Food and Drug Administration (FDA) has approved its Arctic Front(R) Cardiac CryoAblation...
-
Nov 22, 2010
MINNEAPOLIS & MOUNTAIN VIEW, Calif., Nov 22, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) and privately-held Ardian, Inc. announced today that they have entered into a merger agreement...
-
Nov 19, 2010PICTURE Registry Results Published Online Today in EP-Europace
MINNEAPOLIS, Nov 19, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced the publication of data showing that use of its Reveal(R) family of Insertable Cardiac Monitors led to...
-
Aug 26, 2010Medtronic Ablation Frontiers Cardiac Ablation System Delivers Treatment for the Most Common Heart Arrhythmia
MINNEAPOLIS & BRAMPTON, Ontario, Aug 26, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac...
-
Aug 12, 2010
MINNEAPOLIS, Aug 12, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced it has completed its acquisition of ATS Medical, Inc. following payment of $4.00 per share in cash for each...
-
Jun 18, 2010Data from FAST-PVI Study Presented at Cardiostim 2010
MINNEAPOLIS, & NICE, France, Jun 18, 2010 (BUSINESS WIRE) --Data from the FAST-PVI study, supported by Medtronic, Inc. (NYSE: MDT), shows lab time using anatomically-designed ablation catheters...
-
May 30, 2010Clinical Trial of Surgical Tissue Ablation Includes Two U.S. IDE Studies
MINNEAPOLIS, May 03, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), today announced completion of patient enrollment in the first of two studies in the company's CURE-AF (Concomitant...
-
May 25, 2010International Revenue Growth of 20 Percent
MINNEAPOLIS, May 25, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT): First $4 Billion Sales Quarter in Company History Full Year Revenue of $15.8 Billion Increased 8 Percent Full Year Non-GAAP...
-
May 14, 2010Shareholders Invited to Attend Annual Meeting on Aug. 25, 2010
MINNEAPOLIS & DENVER, May 14, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today released new STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial data showing the...
-
May 14, 2010Trial Demonstrates Significant Decrease in Symptoms and Improved Quality of Life for AF Patients Treated with Arctic Front(R) Cardiac CryoAblation Catheter
MINNEAPOLIS & DENVER, May 14, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today released new STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial data showing the...
-
Apr 29, 2010Acquisition Will Expand Access to Innovative Treatment Options for Structural Heart Disease
MINNEAPOLIS, Apr 29, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT), and ATS Medical, Inc. (NASDAQ:ATSI), today announced that the companies have signed a definitive agreement under which...
-
Mar 15, 2010Safety and Effectiveness Trial Evaluated the Arctic Front(R) Cardiac CryoAblation Catheter System for the Treatment of Paroxysmal Atrial Fibrillation
MINNEAPOLIS & ATLANTA, Mar 15, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced data from the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial...
-
Jan 28, 2010First Release of STOP-AF Data on Medtronic Arctic Front(R) Cryoballoon for Paroxysmal Atrial Fibrillation Patients
MINNEAPOLIS, Jan 28, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today pivotal data for the Medtronic Arctic Front(R) CryoAblation Catheter System will be presented as a late...
-
May 23, 2006
MINNEAPOLIS--(BUSINESS WIRE)--May 23, 2006--Medtronic, Inc. (NYSE:MDT): Annual Revenue of $11.3 Billion Grew 12% (13% Constant Currency Growth); Fourth Quarter Revenue of $3.1 Billion Grew 11%...
-
Nov 16, 2005
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 16, 2005--Medtronic, Inc. (NYSE:MDT): -- Implantable Cardioverter Defibrillator (ICD) Revenues Grew 34%; Worldwide Market Share Continued to Increase -- Spinal...
-
May 24, 2005
Medtronic, Inc. (NYSE:MDT): -- Implantable Cardioverter Defibrillator (ICD) Revenues of $682 million in the Quarter Increases Medtronic Worldwide ICD Market Share to 50 Percent -- Spinal Business...
-
Aug 18, 2004
MINNEAPOLIS--(BUSINESS WIRE)--Aug. 18, 2004-- Broad Based Growth Was Led By 31 Percent Increase In Quarterly Implantable Defibrillator Revenues Medtronic, Inc. (NYSE:MDT) today announced quarterly...
-
May 4, 2004
MINNEAPOLIS--(BUSINESS WIRE)--May 24, 2004--Medtronic, Inc. (NYSE:MDT) today announced record quarterly revenues of $2.665 billion, an increase of 24.1 percent over the $2.148 billion of the...
-
Feb 10, 2004
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 11, 2004-- Record Quarterly Performance Led by Greater Than 15 Percent Growth in Spinal, Implantable Defibrillators, Diabetes and Vascular Drawing upon the...
-
Nov 12, 2003
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 12, 2003-- Record Quarter Led by Continued Strong Growth in Implantable Defibrillator and Spinal Revenues, Together With Accelerated Growth in Diabetes; All...
-
Aug 12, 2003
MINNEAPOLIS--(BUSINESS WIRE)--Aug. 12, 2003-- Continued Strong Performances in Cardiac Rhythm Management, Spinal and Neurological Spur Growth Continuing to benefit from widespread acceptance of...
-
Nov 17, 2001Spinal Products and Implantable Defibrillators, Two of Medtronic's Largest Product Lines, Led Second-Quarter Growth
MINNEAPOLIS, Nov 17, 2004 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced quarterly net earnings of $535.7 million, or $0.44 per diluted share, an increase of 13 percent over the...